The News
A bipartisan insulin pricing deal in the Senate now has enough votes to clear a filibuster, according to details first shared with Semafor.
Sens. Jim Banks, R-Ind., and Cory Booker, D-N.J., are newly joining the effort to lower monthly insulin prices to $35 for Americans on employer-sponsored or private insurance, a deal forged by Sens. Jeanne Shaheen, D-N.H., Susan Collins, R-Maine, John Kennedy, R-La., and Raphael Warnock, D-Ga.
Several Republicans signed on this week, and Banks is the 13th to co-sponsor the bill — a magic number in the Senate.
The entire 47-member Senate Democratic Caucus is expected to support the bill, according to a person familiar with the plans, meaning it now has the needed 60 votes to overcome the filibuster and pass.
There could be political benefits for both parties if the bill gets on the Senate floor this year.
Know More
It’s not surprising the proposal has accumulated so much support, given polling shows it’s good politics. A survey from Blue Rose Research shared with Semafor shows 68% of Americans support capping the price of insulin, including 63% of Donald Trump voters and a majority of people who did not vote in 2024. Democrats have a 45-36 edge over Republicans among voters when it comes to who they trust to bring down prices, according to the poll.
With Republicans in control of Washington and Trump trying to bring down drug prices as part of his agenda, the insulin bill could be a rare bipartisan bright spot before the election.